{"preliminary_commentary":{"by_channel":{"x_thread":5,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"C3NIRA","nct_id":"NCT04592237","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=c3nira-nct04592237. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Group I (niraparib)","type":"EXPERIMENTAL"},{"description":"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Group II (cetrelimab, niraparib)","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Aggressive Variant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cabazitaxel","otherNames":["Jevtana","RPR-116258A","Taxoid XRP6258","XRP-6258"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Cetrelimab","otherNames":["JNJ 63723283","JNJ-63723283","JNJ63723283","WHO 10757"],"type":"BIOLOGICAL"},{"name":"Niraparib","otherNames":["MK-4827","MK4827"],"type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"Time from randomization until documented disease progression, start of new therapy for prostate cancer in the absence of progression, or death in the absence of progression, whichever comes first, assessed up to 5 years"}],"references":[],"start_date":{"date":"2020-12-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04592237"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/c3nira-nct04592237"}